Aromita 1 Tablet

Description of Aromita 1 (Anastrozole 1mg) tablet

Aromatase inhibitor (Aromita 1 tablet) is a non-steroidal anti-inflammatory, anastrozole 1mg, which is used as the first line of adjuvant therapy in the treatment of hormone-receptor-positive breast cancer in postmenopausal women. The pharmacodynamic mechanism of the drug is by lowering the systemic oestrogen levels; some breast tumours are oestrogen-dependent and the agent decreases the amount of oestrogen in the body, which in turn decreases the growth of the tumour and the likelihood of recurrence following primary therapy.

Indications of Aromita 1 (Anastrozole 1mg) tablet

Aromita 1 is indicated in the adjuvant treatment of early-stage breast cancer in postmenopausal women with a positive hormone receptor and in the management of advanced or metastatic cancer. It is also regulated regularly following surgical cure or following the tamoxifen therapy to decrease the likelihood of recurrence.

Mechanism of action of Aromita 1 (Anastrozole 1mg) tablet  

Anastrozole is a selective aromatase inhibitor (cytochrome P45019A1) and thus it inhibits the peripheral androgen-to-oestrogen conversion. This enzyme route is the major source of oestrogen in the postmenopausal woman. Inhibiting aromatase, anastrozole significantly reduces the oestrogen levels in the plasma, thus, reducing the stimulation of tumour cells relying on oestrogen, and decelerating the oncological progression.

How to consume of Aromita 1 (Anastrozole 1mg) tablet

The optimal dosage schedule should be a single tablet per day at a fixed time. The tablet can be consumed either with or without food. The entire tablet should be taken whole with water and not crushed and chewed as this can change kinetics of absorption. The therapy can take many years depending on the stage of the disease and response to clinical therapy.

Side Effects of Aromita 1 (Anastrozole 1mg) tablet

1. Common side effects

• Hot flashes
• Fatigue or weakness
• Headache
• Pain in the bones

2. Serious side effects

• Loss of bone mineral loss resulting in osteoporosis
• Increased rate of fractures
• Allergic issues (rashes itchy, or swelling)

3. Rare side effects

• Severe allergic reactions
• Heart attacks or other complications like angine
• Drastic changes of mood and effect

Safety Advice for Aromita 1 (Anastrozole 1mg) tablet

Patients taking Anastrozole ought to have routine medical cheque-ups, such as bone mineral density assessment and lipid profile cheques. Since the medication suppresses oestrogen, prolonged use can cause bone demineralisation and cause a risk of fracture.

Breastfeeding: The drug should not be used in the course of lactation, which can have a negative effect on the baby.

Pregnancy: Anastrozole is not to be used in pregnancy because of the possible harm of the fetus.

Alcohol: Intake of alcohol should be restricted since it can increase the side effect on the liver.

Liver: It is recommended that care be used in patients with hepatic impairment; periodical observation of liver functions is necessary.

Lungs: Pulmonary toxicity is not a common condition, but the patients are advised to report the new onset or worsening of cough, dyspnea, and chest pain to their doctor.

Kidney: Care should be taken in case of severe kidney failure.

Driving: Dizziness or fatigue may result with the use of the drug; patients should avoid driving or using heavy machinery in case of these effects.

Interaction of Aromita 1 (Anastrozole 1mg) tablet

• Drug-Drug Interaction :

Rifampicin × Anastrozole

Rifampicin is a strong inducer of the hepatic enzyme and can reduce plasma levels of Anastrozole, which can negatively impact the anticancer effects of such a drug. It is recommended that clinical monitoring is done.

Phenytoin × Anastrozole

Phenytoin can interact with anastrozole such that the hepatic metabolism of anastrozole increases faster thus resulting in lower drug levels. Therapeutic monitoring and precaution is therefore recommended.

Carbamazepine × Anastrozole

Carbamazepine is likely to enhance the hepatic enzyme activity thus lowering the concentration and efficacy of Anastrozole.

Warfarin × Anastrozole

Though a considerable interaction is not usual; it is recommended that monitoring be applied when the two drugs are used simultaneously because of anticoagulant response changes.

Ketoconazole × Anastrozole

Ketoconazole which is an inhibitor of CYP enzyme can increase the plasma levels of Anastrozole. Special attention to side effects should be followed.

• Drug-Food Interaction:

It has not been reported that Anastrozole and food had any significant interaction in pharmacokinetics. Tablet can be given with or without concomitant food as per the choice of the patient or as per clinically convenient.

• Drug-Disease Interaction:

Osteoporosis:

Anastrozole leads to low oestrogen levels through long-term exposure, which may lead to a decrease in bone mineral density and increase the risk of fracture. Probably, bone density monitoring and calcium and vitamin D supplementation can be justified in patients with already existing osteoporosis or decreased bone mass.

Cardiovascular Disease:

Anastrozole can increase the level of cholesterol and this may result in the development of cardiovascular risk. Close observation should be done on patients who have a history of heart disease or hyperlipidemia.

Hepatic Impairment:

The Anastrozole metabolism in the liver dysfunctioned patients can be altered. During therapy, liver functioning tests are to be observed.

Renal Impairment:

Even though the dosage does not require any adjustment, it is advisable to be cautious in cases of extreme dysfunction of the kidneys.

Contraindication of Aromita 1 (Anastrozole 1mg) tablet

Anastrozole should not be used in those people who show signs of hypersensitivity to the active substance or any excipients. It should not be used in pregnancy and lactation because it has teratogenic and infantile adverse effects. The drug is not recommended in premenopausal patients unless accompanied by the ovarian suppression therapy since the pharmacologic effect is dependent on the pathways that are active in the postmenopausal oestrogen environment.

Dosage of Aromita 1 (Anastrozole 1mg) tablet   

The typical therapeutic protocol includes 1mg/day of medication taken at a point in time that is regular daily. The total period of treatment is also personalised and determines the treating oncologist and may take several years depending on clinical goals and treatment effectiveness.

Storage of Aromita 1 (Anastrozole 1mg) tablet  

Store the formulation at ambient temperature, without the invasion of any moisture content or thermal decadence. These medicines should be kept in locked premises in order to avoid accidental access by the paediatrics.

Missed Dose of Aromita 1 (Anastrozole 1mg) tablet

In case of dose omission, one should take as soon as possible, but a significant period should be between one scheduled dose and the next.

Other General Information of Aromita 1 (Anastrozole 1mg) tablet

In its long-term use, it may lead to dermatologic dryness and permanent joint stiffness; it is advised to apply ample hydration and light exercise to alleviate pain. To keep the skeletal health, patients should have a diet rich in calcium and vitamin D, as well as participate in regular weight-bearing exercises provided they can do them medically. It is recommended that regular follow-ups with the oncologist should be done to determine the effectiveness of the therapy and detect adverse events early enough. Patients are advised to inform their physician immediately, in case they are having persistent bone pain, chest pains, or pronounced physical fatigue.

FAQs of Aromita 1 (Anastrozole 1mg) tablet  

1. Why is it that Anastrozole is only used in postmenopausal women?

Anastrozole works by blocking aromatase which is an enzyme that produces oestrogen after menopause. In premenopausal women, ovarian activity is still capable of generating the large amount of oestrogen; hence the effects of a drug are constrained unless the ovarian suppression is performed simultaneously.

2. Is Anastrozole associated with bone weakness?

Yes. Oestrogen is necessary in preserving bone density and its depletion may gradually weaken bone. Bone density cheques are commonly prescribed by the clinicians as long-term treatment.

3. Is Anastrozole a weight gaining drug?

Direct adverse effects are not common, but weight gain may be caused by hormonal changes, a lack of exercise owing to fatigue in some patients.

4. What is the average length of time Anastrozole should be used?

The drug is used normally in a period of five years and above depending on the staging of the tumour, the risk of its recurrence and the judgement of the physician who is treating the patient.

5. Is it possible that Anastrozole influences cholesterol level?

Indeed. Others might develop hypercholesterolemia, and this will be a reason to repeat lipid profile monitoring.

6. Do you experience joint pain in the course of treatment?

Such symptoms as arthralgia and stiffness in the joints are common as a result of oestrogen deprivation. These complaints can be treated by gentle physical activities and supportive therapies.

Fact Box of Aromita 1 (Anastrozole 1mg) tablet  

Field	Details
Generic/Molecule Name	Anastrozole
Therapeutic Class	Anti-neoplastic agent
Pharmacological Class	Aromatase Inhibitor
Dosage form	Tablet
Habit forming	No
Indication	Hormone Receptor-positive Breast cancer

 

References